Monday, 23 May 2022



LATEST NEWS Skill Development Centre to come up in Khatkar Kalan 12 youth get jobs at counselling-cum-job camp at Khatkar Kalan Munmum Dutta aka Babita Ji Might Quit TMKOC. Here’s The Reason Kamal Haasan's 'Vikram' trailer receives a thunderous response at Cannes Film Festival IPL 2022: Hardik Pandya's captaincy has been a big part of our success, says Vikram Solanki Europe's red alert for monkeypox as nations told to prepare vaccination strategies First look of Adil Hussain's 'Footprints On Water' unveils at Cannes Film Festival Laura Dern defends age gap between her and Sam Neill in 'Jurassic Park' Adah Sharma takes rigorous sword fighting lessons for her next Rajpal Yadav was mistaken for a transgender while shooting for 'Ardh' 3 LeT militants, associate arrested for J&K sarpanch's murder Abhimanyu Dassani prepared himself for 'Nikamma' by re-watching Govinda films K-pop band Tomorrow X Together debuts at No. 4 on Billboard 200 Amit Shah visits Prime Ministers' museum 'Dhappa' cast opens up on their show which deals with love and romance Akhil Akkineni's 'Agent' locks its OTT partner Vikrant Rona’s First Song ‘Ra Ra Rakkamma’ In The Kannada Language Is Out. Watch Video '9 Hours' trailer shows up the violent side of robberies 'The Storyteller': Paresh Rawal, Adil Hussain to come together for adaptation of Ray classic Nitish Kumar reportedly to have asked all his MLAs to stay put in Patna Manchester City players hail Premier League title win as 'unbelievable achievement'


Russian vaccine found safe in early human trials: Lancet

Web Admin

Web Admin

5 Dariya News

London , 04 Sep 2020

A Russian Covid-19 vaccine has shown no serious side effects and elicited an immune response in early human trials, said a study published in The Lancet on Friday.Russia last month registered the "Sputnik V", becoming the first country to approve a Covid-19 vaccine.However, the country faced criticism for approving a vaccine before completion of Phase-3 trials.According to the study, published in The Lancet, the researchers enrolled 76 healthy adult volunteers (aged 18-60 years) for the two Phase-1 and Phase-2 studies -- 38 people in each study.In Phase-1 of the study, two groups of nine volunteers received one dose of either recombinant adenovirus type 26 (rAd26) vector or recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for SARS-CoV-2 spike glycoprotein (rAd26-S and rAd5-S), in frozen form.In Phase-2, another group of 20 healthy adult volunteers in each study received sequential doses of rAd26-S followed by rAd5-S of one of the two formulations.Adverse events were mostly mild, with the most common adverse events being pain at the injection site, hyperthermia, headache, asthenia, and muscle and joint pain, said the study.Both formulations of the vaccine were immunogenic in all participants, inducing neutralising humoral and cell-mediated responses, said the study.In Phase-2, 85 per cent of participants had detectable antibodies at 14 days after the priming dose, rising to 100 per cent by day 21, the results showed."The two 42-day trials - including 38 healthy adults each - did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response," the study's authors wrote.The study's authors also held that large, long-term trials, including a placebo comparison, and further monitoring are needed to establish the long-term safety and effectiveness of the vaccine for preventing Covid-19 infection.Reports suggest that Russia is planning a Phase-3 trial of the vaccine involving 40,000 people.


Tags: Coronavirus , COVID 19 , Novel Coronavirus , India Fights Corona , Fight Against Corona , Stay Home Stay Safe , Stay Home , Corona Virus Updates , Coronavirus Epidemic , Coronavirus Pandemic , Corona virus threat , Corona Outbreak , Covid-19 vaccine , Russian Covid-19 vaccine , Lancet , Sputnik V



related news




Photo Gallery



Video Gallery



5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2022 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD